Sequence 26 from Patent US 20060122119

General Information


DRACP ID  DRACP01282

Peptide Name   Sequence 26 from Patent US 20060122119

Sequence  TPRLPSSADVE

Sequence Length  11

UniProt ID  P11344  Q8MIU0  P54834  Q9BDE0  P55033  P14679 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01282

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C49H82N14O19

Absent amino acids  CFGHIKMNQWY

Common amino acids  PS

Mass  134981

Pl  4.18

Basic residues  1

Acidic residues  2

Hydrophobic residues  3

Net charge  -1

Boman Index  -2905

Hydrophobicity  -65.45

Aliphatic Index  70.91

Half Life 
  Mammalian: 7.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3 




DRACP is developed by Dr.Zheng's team.